1Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with untreatable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Cancer , 1987,59: 1874-1881.
2Chang A, Kim K, Glick J, et al. Phase Ⅱ study of taxol, merbarone and piroxantrone in stage Ⅳ non-small cell lung cancer: the East Cooperative Oncology Group results. J Natl Cancer Inst, 1993,85: 388-394.
3Murchy WK, Fossella FV, Winn R J, et al. Phase Ⅱ study of taxol in patients with untreated advanced non-small cell lung cancer. J Natl Cancer Inst, 1993,85: 384-388.
4Zanelli GD,Quaia M,Robieux I,et al. Paclitaxel as a radiosensitiser :a proposed schedule of administration based on in vitro data and pharmacokinetic calculations. Eur J Cancer , 1997,33:486-492.
5Milas L, Hunter NR, Mason KA. Role of reoxygenation in induction of enhancement of tumor radioresponse by paclitaxel. Cancer Res, 1995,55: 3564-3568.
6Georgiadis MS, Russell EK, Gazdar AF, et al. Paclitaxel cytotoxicity against human lung cancer lines increases with prolonged exposure durations. Clin Cancer Res,1997, 3:449-454.
7Tishler RB, Schiff PB, Geard CR, et al. Taxol: a novel radiation sensitiser. Int J Radiat Oncol Biol Phys, 1992,22:613-617.
8Liebmann J, Cook JA, Fisher J, et al. Changes in radiation survival curve parameters in human tumor and rodent cells exposed to taxol (paclitaxel). Int J Rdiat Oncol Biol Phys, 1994,29:559-564.
9Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Nantl Cancer inst, 1999,86:441-446.
10Geard CR,Jones JM, Shift PB. Taxol and radiation. J Nantl Cancer Inst Monogr , 1993,15:89-94.
